GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.

GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.